Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer

Article Oncology

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Susanne Flach et al.

Summary: This study demonstrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and shows the feasibility of personalized ctDNA assays for disease detection prior to clinical recurrence.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer

Robert L. Ferris et al.

Summary: This study investigated the addition of ipilimumab to standard cetuximab-radiotherapy for the treatment of HNSCC. The results showed that the regimen was tolerable and achieved acceptable survival rates. Additionally, high expression of coinhibitory receptors on baseline tumor-infiltrating lymphocytes was associated with poorer disease-free survival.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma

Catherine T. Haring et al.

Summary: HPV-related OPSCC shows better outcomes compared to non-virally mediated disease. Clinical trials are actively investigating deescalation strategies while emphasizing the importance of biomarkers like ctDNA in treatment response and disease recurrence monitoring.

ORAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco et al.

Summary: The study aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic head and neck squamous cell carcinoma. Results showed a 45% overall response rate at 6 months for the combination of pembrolizumab and cetuximab.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidemoid carcinoma

M. E. Heft Neal et al.

Summary: This study conducted full characterization of five independent HCCC cases, revealing insulin-like growth factor alterations and identifying a 354 gene signature that can differentiate HCCC from MEC. The study also discovered elevated expression of ATF1 binding motif-enriched genes in HCCC, supporting a transcriptional pathogenic mechanism related to EWSR1-ATF1 fusion. Furthermore, analysis showed elevated levels of IGF1R, SGK1, SGK3, and CXCR4 protein in HCCC cases, potentially providing actionable alterations for clinical care.

ORAL ONCOLOGY (2021)

添加到收藏夹

Article Otorhinolaryngology